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Detection of external irritants by head nociceptor neurons has deep evolutionary roots. Irritant-induced
aversive behavior is a popular pain model in laboratory animals. It is used widely in the formalin model,
where formaldehyde is injected into the rodent paw, eliciting quantiﬁable nocifensive behavior that has a
direct, tissue-injury-evoked phase, and a subsequent tonic phase caused by neural maladaptation. The
formalin model has elucidated many antipain compounds and pain-modulating signaling pathways.
We have adopted this model to trigeminally innervated territories in mice. In addition, we examined
the involvement of TRPV4 channels in formalin-evoked trigeminal pain behavior because TRPV4 is abun-
dantly expressed in trigeminal ganglion (TG) sensory neurons, and because we have recently deﬁned
TRPV4’s role in response to airborne irritants and in a model for temporomandibular joint pain. We found
TRPV4 to be important for trigeminal nocifensive behavior evoked by formalin whisker pad injections.
This conclusion is supported by studies with Trpv4/ mice and TRPV4-speciﬁc antagonists. Our results
imply TRPV4 in MEK-ERK activation in TG sensory neurons. Furthermore, cellular studies in primary
TG neurons and in heterologous TRPV4-expressing cells suggest that TRPV4 can be activated directly
by formalin to gate Ca2+. Using TRPA1-blocker and Trpa1/ mice, we found that both TRP channels
co-contribute to the formalin trigeminal pain response. These results imply TRPV4 as an important
signaling molecule in irritation-evoked trigeminal pain. TRPV4-antagonistic therapies can therefore be
envisioned as novel analgesics, possibly for speciﬁc targeting of trigeminal pain disorders, such as
migraine, headaches, temporomandibular joint, facial, and dental pain, and irritation of trigeminally
innervated surface epithelia.
 2014 The Authors. Published by Elsevier B.V. on behalf of International Association for the Study of
Pain. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/
by-nc-sa/3.0/).1. Introduction Although some progress has been made, the molecules that senseThe trigeminal sensory system enables vertebrate animals to
detect a wide range of environmental stimuli, including noxious
cues such as chemical irritants. Detection of environmental irri-
tants by the trigeminal system subserves a sentinel function that
has enhanced evolutionary ﬁtness of the respective species.the chemical irritants and signal the noxious cue in the trigeminal
system remain largely elusive.
Formalin is a prototypical irritant that has been formulated in
aqueous solution so that it can be injected into tissue. In the study
of pain, the formalin model has led to profound insights on analge-
sic potency of candidate drugs and to elucidation of signaling path-
ways related to pain [9,14,17,32,34,35]. Formalin is an electrophile
and reacts with a variety of amino acids by nucleophilic addition. It
also irreversibly cross-links proteins. These chemical properties of
formalin have been viewed as contributory to tissue injury. Via
these mechanisms, formalin can also directly irritate nerve termi-
nals of nociceptor neurons. Together, these events are viewed as
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there are speciﬁc protein targets that are critical for formalin-
evoked pain and their eventual identity is largely unknown. How-
ever, TRPA1 channels have been implicated as critical regulators of
the formalin behavioral response as well as in the response to for-
malin and other electrophilic irritants in heterologous cellular sys-
tems [23,24]. This raises the question whether other molecules, in
particular another TRP ion channel, could play a role in response to
formalin.
Practically, extratrigeminal somatosensory exposure to forma-
lin in humans virtually does not occur as a pain-eliciting or -facil-
itating condition [38], yet airborne trigeminal exposures facilitate
headaches and local painful irritations of conjunctivae of the eyes,
sinuses, and upper airways [25,29]. However, most reported appli-
cations of the formalin model is extratrigeminal, with formalin
injection to the hind paw. Therefore, one of our main rationales
was to adapt the formalin model to trigeminally innervated areas
[5,22] in a mouse model. In terms of which mouse line to subject
to trigeminal formalin injections, we decided to use Trpv4/ mice
so that the role of TRPV4 in trigeminal irritant pain could be
assessed, based on our previous ﬁndings that TRPV4 was critical
for airborne irritation in upper airways [19] and a key contributor
to temporomandibular joint (TMJ) pain induced by arthritogenic
irritant [8].
Our results demonstrate an essential role for TRPV4 in the tri-
geminal formalin response in vivo, in TRPV4 activation by formalin
in trigeminal ganglion (TG) sensory neurons, and in heterologous
cellular systems. Our ﬁndings reiterate the concept that TRPV4
forms a relevant target in trigeminal pain via its expression in TG
sensory neurons.
2. Materials and methods
2.1. Animals
The pan-null phenotype of Trpv4/ mice relies on excision of
the exon encoding transmembrane domains 5 and 6. Mice were
outcrossed to C57BL/6J background and genotyped by PCR [21].
Trpa1/ mice (B6;129P-Trpa1tm1Kykw/J) were from the laboratories
of Drs Robert W. Gereau (Washington University) and Ru-rong Ji
(Duke University). Male wild-type (WT) (C57BL/6J), Trpv4/, and
Trpa1/ mice, 2 to 2.5 months of age, were used for all
experiments.
Epidermal-speciﬁc, Tamoxifen (tam)-inducible Trpv4 knock-
down mice were created as previously described [26]. In brief,
the Trpv4 genomic locus was engineered so that loxP sites
surrounded exon 13, which encodes TM5–6. This mutation was
propagated in mice that were crossed to K14-CRE-ERtam mice,
so that ((Trpv4lox/lox)X(K14-CRE-ERtam)) mice could be induced
by tam administration via oral gavage for 5 consecutive days
at 6 mg/day in 0.3 mL corn oil, at age 2 to 2.5 months of age,
plus a one-time booster 2 weeks after the last application. Con-
trol animals received the same volume of corn oil. Efﬁciency of
targeting was veriﬁed by qRT-PCR and immunohistochemistry
for Trpv4 expression in skin at the gene and protein level,
respectively [26].
Male dominant-negative mitogen-activated protein kinase
kinase (dnMEK) transgenic mice, 2 to 2.5 months of age, were used.
The neuron-speciﬁc and pan-neuronal Ta1 a-tubulin promoter
was used to drive the transgene [31]. We documented expression
of dnMEK in TG sensory neurons [8].
Animals were housed in climate-controlled rooms on a
12/12 h light/dark cycle with water and standardized rodent
diet available ad libitum. All animal protocols were approved
by the Duke University IACUC in compliance with NIH
guidelines.2.2. Formalin-induced pain behavior and chemical injections
Mice were allowed to acclimate to a Plexiglas chamber for at
least 30 min before testing, and they received 10 lL subcutaneous
injection of 4% of formalin (diluted from an aqueous solution of
commercial 37% formaldehyde with normal saline) through a
30-gauge needle or saline into the right whisker pad or into the
right hind paw [22]. After injection, mice were immediately placed
back in chamber, and rubbing behavior was recorded by a Pana-
sonic videocamera for a 45 min observation period. The recording
time was divided into 9 blocks of 5 min, and a nociceptive score
was determined per block by measuring the time that the animals
spent rubbing the injected area predominantly with the ipsilateral
forepaw and rarely with hind paw for whisker pad injection, and
the time spent licking, ﬂicking, and lifting the injected hind paw.
The rubbing behavior with forepaw is evoked by pain, which is dis-
tinct from itch behavior [33]. Behavioral analysis was conducted by
observers blinded to genotype.
To investigate the effects of the speciﬁc TRPV4 inhibitor
HC067047 or GSK205 on formalin-induced nociceptive behavior,
mice received a single intraperitoneal administration of
HC067047 (dissolved in 6% DMSO; Sigma) or received a single sub-
cutaneous injection of GSK205 into the whisker pad (10 lL, dis-
solved in 4% DMSO) 15 min before formalin injection. For testing
the effect of 4a-PDD (10 lL, dissolved in 4% DMSO), a speciﬁc ago-
nist of TRPV4, on pain behavior, mice received a subcutaneous
injection into the whisker pad. In addition, to investigate the
effects of the speciﬁc MEK inhibitor U0126 on formalin-induced
nociceptive behavior, mice received a single subcutaneous injec-
tion of U0126 into the whisker pad (10 lL, dissolved in 20% DMSO)
15 min before formalin injection. Control animals received the
same volume of normal saline, or 4%, 6%, or 20% of DMSO.
2.3. Immunohistochemistry, morphometry analysis, and neural tracing
Routine procedures were followed [8]. Brieﬂy, mice were
perfused transcardially with 0.01 M phosphate-buffered saline
followed by ice-cold 4% paraformaldehyde (PFA) at the experimen-
tal time point under study. Their TGs and whisker pad skin were
dissected and postﬁxed in 4% PFA overnight, cryoprotected in
20% sucrose (48 h) and sectioned on a cryostat at 12 and 20 lm,
respectively. Sections were blocked with 5% normal goat serum
(Jackson) and incubated overnight with primary antibodies: rabbit
anti-TRPV4 (1:300, Abcam), mouse anti-Keratin 14 (1:200, Santa
Cruz), guinea pig anti-PGP 9.5 (1:500, Neuromics), rabbit anti-
phospho-ERK (pERK, 1:250, Cell Signaling Technology), and mouse
anti-pERK (1:600, Cell Signaling Technology; for double-labeling
with TRPV4 in TG). Immunodetection was accomplished with sec-
ondary antibodies (AlexaFluor 594–conjugated goat anti-rabbit;
AlexaFluor 488–conjugated goat anti-mouse or anti–guinea pig;
all 1:500; Invitrogen) for 2 h, and coverslipped with Vectashield
(Vector). Digital micrographs were acquired using a BX61 Olympus
upright microscope equipped with a high-resolution CCD camera
and with constant acquisition/exposure settings using ISEE soft-
ware (ISEE Imaging Systems).
To track whisker pad skin innervation of TRPV4 and/or pERK
expressing TG neurons, mice were injected with 1.5 lL of neural
tracer Fast Blue (2% aqueous solution, Polysciences) into the whis-
ker pad 2 days before normal saline or 4% formalin administration.
At 5 min after the last injection, mice were perfused, and tissues
were immunostained as described above.
For every animal under study, 4 to 6 TG sections were analyzed
per mouse; neurons were identiﬁed by morphology. The cutoff
density threshold was determined by averaging the density of 3
neurons per section that were judged to be minimally positive by
using ImageJ software. All neurons for which the mean density
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were expressed as the percentage of total counted TG neurons.
2.4. Western blot analysis
Routine procedures were followed [8]. Brieﬂy, snap-frozen TGs
and whisker pad skin were protein extracted in CHAPS, then elec-
troblotted to nitrocellulose membranes after gel separation of pro-
teins in a 10% polyacrylamide gel. Membranes were blocked with
5% dry milk; pERK and ERK were speciﬁcally detected with primary
antibodies (rabbit anti-pERK and anti-ERK, both at 1:500; Cell
Signaling Technology), secondary antibody (anti-rabbit
peroxidase-conjugated, 1:5000; Jackson ImmunoResearch), and
chemoluminescence substrate (ECL-Advance, GE Healthcare).
Abundance was quantiﬁed using ImagePro Plus software. b-Actin,
as a control, was detected with a mouse monoclonal anti-b-actin
antibody (clone AC-5, 1:500; Abcam).
2.5. Cell culture and Ca2+ imaging
N2a cells were cultured on poly-D-lysine and laminin coated
coverslips in a 24-well plate containing DMEM (Sigma) supple-
mented with 10% bovine serum and penicillin/streptomycin. After
24 h, cells were transfected with rTRPV4-GFP or GFP alone (con-
trol) using the Lipofectamine 2000 protocol (Invitrogen).
TGs from 1.5- to 2-month-old male WT and Trpv4/mice were
dissected and digested with 1 mg/mL collagenase (Worthington,
CSL1) and 5 mg/mL dispase (Invitrogen) for 45 min, then triturated
[6]. The resulting cell suspension was ﬁltered through a 70 lm cell
strainer (BD Falcon) to remove debris. Neurons were cultured in
DH10 medium (1:1 DMEM:Ham F12, Invitrogen) with 10% fetal
bovine serum (Sigma), 100 U/mL penicillin and 100 lg/mL strepto-
mycin (Gibco), and 50 ng/mL nerve growth factor (USBiological) on
coverslips coated with poly-D-lysine and laminin (Invitrogen), and
incubated with 5% CO2 at 37C. Ca2+ imaging was performed the
day after culture.
Primary mouse keratinocytes were cultured as previously
described [26]. The epidermis from back skin of newborn WT mice
was separated from the dermis by a 1 h dispase (BD Biosciences)
treatment. Then the keratinocytes were dissociated from the epi-
dermis using trypsin (Gibco). Keratinocytes were plated on colla-
gen-coated dishes or glass coverslips and grown in keratinocyte
serum-free media (Gibco) supplemented with bovine pituitary
extract and epidermal growth factor (R&D Systems), 100 pmol chol-
era toxin (Calbiochem), and 1 antibiotics/antimycotics (Gibco) in
an incubator at 5% CO2 and 37C.
Ca2+ imaging of primary TG neurons and epidermal keratino-
cytes in response to formalin was conducted after loading with
2 lM fura2-AM (Invitrogen) for 30 min, following a ratiometric
Ca2+-imaging protocol with 340/380 nm blue light for dual excita-
tion [26]. Ratios of emissions were acquired at 0.5 Hz. DR/R0 was
determined as the fraction of the increase of a given ratio over
baseline ratio, divided by the baseline ratio.
To investigate the effects of the speciﬁc TRPV4 inhibitor GSK205
[26,28] or TRPA1 inhibitor A-967079 [7,30] on formalin-induced
Ca2+ inﬂux, cells were incubated with GSK205 or A-967079
15 min before formalin stimulation.
2.6. Electrophysiology
Heterologously transfected N2a cells were recorded as described
previously [19]. Patch clamp recordings were performed 24 h after
transfection. Brieﬂy, cultured cells on individual coverslips were
incubated for 10 min at 37C in extracellular solution containing
(mM) 1 MgCl2, 10 glucose, 10 HEPES, 145 NaCl, and 2 CaCl2 (pH7.4, 310 mOsM). Cells were then transferred to a recording chamber
staged on an inverted Leica microscope that was equipped with
ﬂuorescent ﬁlters. Each GFP labeled cell was identiﬁed for whole
cell currents recording using a glass electrode. The glass electrodes
were pulled (P-80/PC; Sutter Instruments) from borosilicate glass
capillaries (Warner Instruments) and had resistances of 2.5 to
3.0 MX. Before recording, the glass electrodes were ﬁlled with
intracellular solution containing (mM) 140 CsCl, 10 HEPES, 1 EGTA,
0.3 Na-GTP, 2 Na2-ATP, and 2MgCl2 (pH 7.4, 295 mOsM).Whole cell
currents were recorded using pclamp 9 software (Molecular
Devices) and Axopatch 200B ampliﬁer (Axon Instruments). The cell
was ﬁrst clamped at 65 mV in voltage clampmode, and a 1 s volt-
age ramp from 110 mV to +120 mV was applied every 2 seconds
for 15 to 20 sweeps.
Formalin was only added after a stable baseline was estab-
lished. For recording the effect of TRPV4 inhibitor on formalin, cells
were ﬁrst incubated for 10 min with 10 lM GSK205 before adding
formalin. The recorded data were ﬁltered at 2 kHz and digitized at
10 kHz. The capacitance was monitored during recording and any
data with a ±5 pF change were excluded from analysis. Post-
recording analysis was conducted using clampﬁt 9 software.
2.7. Statistical analysis
All data are expressed as mean ± SEM. Two-tailed t tests or
1-way ANOVA followed by Tukey post hoc test were used for group
comparison. P < .05 indicated statistically signiﬁcant differences.
3. Results
3.1. Trpv4 in TG sensory neurons is essential for formalin-evoked
irritant pain
Subcutaneous injections of minute amounts of diluted formalin
elicit an acute response that lasts approximately 5 min directly
after injection. An intermediary phase is characterized by less pain
behavior for the next 10 min [11]. This is followed by a tonic or late
response for the next 30 to 45 min, again with increased nocifen-
sive behavior, which is sustained by maladaptive neural responses,
demonstrated for sensory relay neurons in the spinal cord dorsal
horn [40].
In laboratory mice of a C57BL/6J genetic background, we found
a biphasic response after whisker pad injection of 10 lL of 4% for-
malin (Fig. 1A). The term ‘‘biphasic’’ has to take into account that
the interphase did not equal lack of nocifensive behavior after sal-
ine injections but was clearly less pronounced than acute or tonic
phase. The acute phase was characterized by half the time spent
with nocifensive behavior, and the tonic phase a third of the time
(Fig. 1B). We selected 4% formalin in a 10 lL injection volume
because this application can produce the most robust nocifensive
behavior [22].
Having elaborated these basics of the irritant behavioral
response to formalin in the trigeminal system, we next subjected
Trpv4/ pan-null mice to formalin injections on the basis of the
rationales laid out above. We found signiﬁcantly attenuated noci-
fensive behavior in these mice for all phases (Fig. 1C, D). This result
indicates that Trpv4 is necessary for both the acute response to tis-
sue injury by formalin in the whisker pad and the protracted tonic
response, which is neurally mediated by the trigeminal system. In
order to conﬁrm and extend these ﬁndings, we preapplied a
TRPV4-selective inhibitor, HC067047 [10], by systemic application.
We obtained similar results as for genetically encoded deletion in
Trpv4/ mice. In addition, attenuation of the tonic phase of the
response was dose dependent (Fig. 1E, F). Acute block of TRPV4
function that leads to a similar result as genetically encoded gene
Fig. 1. Trpv4 in TG sensory neurons is essential for formalin-evoked irritant pain. (A) Time course of the face-rubbing activity observed in naive mice and in mice after
subcutaneous injection of normal saline (NS) or formalin (4%) into the whisker pad. Time that mice spent rubbing is plotted for each 5 min block over 45 min. (B)
Quantiﬁcation of the formalin response binned into different phases: acute phase (0–5 min), interphase (5–15 min), and tonic phase (15–45 min) (⁄⁄⁄P < .001 vs NS).
Signiﬁcant attenuation of irritant pain induced by formalin was observed in mice lacking Trpv4 (C, D; ⁄P < .05, ⁄⁄P < .01 and ⁄⁄⁄P < .001 vs WT: formalin), systemically
pretreated (intraperitoneally) or subcutaneously pretreated with the TRPV4 inhibitor HC067047 (E, F; ⁄⁄P < .01 vs formalin) or GSK205 (G, H; ⁄P < .05, ⁄⁄P < .01 and ⁄⁄⁄P < .001
vs formalin; the absence of off-target effects of GSK205 is demonstrated in Trpv4/ mice), but not in mice with inducible Trpv4 deletions in keratinocytes (I, J). In addition,
mice pretreated with the selective inhibitors showed dose-dependent reduction of rubbing activity for the tonic phase (F, H). Animals injected with the TRPV4 selective
agonist 4a-PDD displayed signiﬁcant rubbing behavior of single phase in a dose-dependent manner that was absent in Trpv4/mice, but was unaffected by ablating Trpv4 in
keratinocytes (K, L; ⁄⁄⁄P < .001 vs NS and #P < .05 vs WT: 0.5mM 4a-PDD); n = 5–9/group; 1-way ANOVA with Tukey post hoc test was used for statistic analyses.
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trigeminal formalin response as observed here, importantly with-
out apparent contribution by genes that are up-regulated in a com-
pensatory manner when deleting Trpv4.
On the basis of the dose-dependent attenuation of the formalin
response by systemic application of TRPV4-inhibitor, HC067047,
we also wanted to learn whether whisker pad injection of a TRPV4
inhibitor had a similar effect or perhaps more pronounced impact
on one speciﬁc response phase. We used the rapid-onset, rapid-
clearance TRPV4-selective blocker GSK205 [19,28,41], which we
have used previously in a sunburn pain model where the com-
pound proved effective upon topical application and devoid of
off-target effects [26]. Surprisingly, the protracted tonic phase
was attenuated more robustly, also in a clearly dose-dependent
manner, by GSK205 than its effects on the acute and interphase
(Fig. 1G, H). One reason for this effect could be the protracted dif-
fusion to reach the compound’s targets for the acute phase. How-
ever, differences in attenuation of the acute phase between
different Trpv4 loss-of-function experiments were moderate.
Importantly, all 3 experiments share the feature that the pro-
tracted neural phase is regulated by TRPV4. The effect we noticedthe most was the response to whisker pad injection of GSK205.
GSK205 off-target effects could not be seen in our trigeminal for-
malin model (Fig. 1H). This result, together with established
insights on the tonic phase of the formalin model, and with known
functional expression of TRPV4 channels in TG sensory neurons
[8,20,21], suggests that the critical site of action for TRPV4 in the
trigeminal formalin response could be in TG sensory neurons.
However, given the robust TRPV4 expression in epidermal kerati-
nocytes [26] (Fig. 5A, B), we also considered a co-contribution by
epidermal TRPV4 to the formalin response, essentially for all 3
phases. We did not ﬁnd evidence in favor of this hypothesis
because we recorded identical abundance of nocifensive behavior
in a Trpv4 keratinocyte-speciﬁc, inducible knockout that we have
developed previously [26]. Induced and sham-induced mice
showed the same robust nocifensive behavior for all 3 phases
(Fig. 1I, J). Thus, TRPV4 channel expression by TG sensory neurons,
including their peripheral projections to the whisker pad, appear to
be key expression sites for the observed nocifensive response in all
3 phases. TRPV4 expression in keratinocytes plays no role, and
rapid migration of other TRPV4-expressing nonneural cells to the
site of injection that subsequently regulate the tonic phase of the
Fig. 2. Extracellular signal–related kinase (ERK) signaling downstream of TRPV4 is critical for formalin-evoked irritant pain. Reduced tonic phase of irritant pain was observed
in the dominant negative mitogen-activated protein kinase kinase (dnMEK) mice (A, B; n = 7–9/group, ⁄⁄P < .01 and ⁄⁄⁄P < .001 vs WT: formalin). Different from the dnMEK
mutant mice, animals subcutaneously pretreated with the selective MEK inhibitor U0126 not only showed reduction of the tonic phase of pain, but also of the acute phase (C,
D; n = 5–9/group, ⁄⁄P < .01 and ⁄⁄⁄P < .001 vs formalin). (E–J) Increase of phospho-ERK (pERK) expressing TG neurons in response to formalin depends on Trpv4. Micrographs
show pERK and total ERK (tERK) expression in the TG and whisker pad skin homogenates as revealed by Western blot analysis (E). Right bar graphs depict quantitation. Note
early and robust increase of pERK expression and unchanged tERK expression in the TG and whisker pad (W.pad) skin after formalin (F, G; n = 5/group, ⁄P < .05, ⁄⁄P < .01 and
⁄⁄⁄P < .001 vs NS). (H, I) Increase of pERK in TG is restricted predominantly to neurons and signiﬁcantly inhibited in mice lacking Trpv4 or pretreated with the TRPV4 selective
inhibitors (n = 4–5/group, ⁄⁄⁄P < .001 vs NS, #P < .05 and ##P < .01 vs WT: formalin). (H, J) Increase of pERK is inhibited in dnMEK mutant mice and in mice pretreated with the
MEK selective inhibitor U0126, as expected (n = 4–5/group, #P < .05, and ###P < .001 vs WT: formalin). One-way ANOVA with Tukey post hoc test was used for (B) and (D), and
2-tailed t test was used for (F), (G), (I), and (J).
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not supported by current understanding of the formalin model.
Therefore, TG sensory neurons are the most likely sites of TRPV4
function in response to whisker pad injection of formalin. This con-
clusion is highly likely for the neurally mediated tonic phase. For
the acute phase, a major contributory role of TRPV4 appears likely.
In order to conduct a gain-of-function study on the role of tri-
geminally expressed TRPV4, we injected TRPV4-selective activa-
tors, 4a-PDD and GSK101 [4,37], into the whisker pad. This led
to a monophasic behavior, reminiscent of the formalin acute phase,
but more protracted and lacking subsequent phases (Fig. 1K, L).
GSK101 proved slightly more potent than 4a-PDD (data not
shown). The elicited behavior was dependent on TRPV4, as shown
by the greatly attenuated response of Trpv4/ mice (Fig. 1K, L).
However, there was also a minor effect in the null background,
pointing toward a marginal off-target effect by 4a-PDD as a tri-
geminal irritant. When using again the keratinocyte-speciﬁc and
inducible Trpv4 knockdown mouse [26], there was identical noci-
fensive behavior in these animals when inducing Trpv4 knockdown
compared with WT (Fig. 1K, L). These ﬁndings suggest that TRPV4
is needed for the nocifensive response to whisker pad injections of
a known TRPV4-selective activator, 4a-PDD, yet suggest that
TRPV4 expression in keratinocytes of the whisker pad skin plays
no role in this behavior.Taken together, loss-of-function experiments on the role of
TRPV4 in the trigeminal formalin response, as well as gain-of-func-
tion experiments on the role of TRPV4 in nocifensive behavior in
response to whisker pad injection of selective TRPV4 activators,
both suggest that TRPV4 is an irritant receptor expressed by and
functional in TG sensory neurons. Robust expression of TRPV4 by
whisker pad skin keratinocytes does not play a role in the nocifen-
sive behavioral response to whisker pad injections of formalin or
selective chemical TRPV4 activators. Furthermore, we excluded
an exclusive trigeminal role of TRPV4 in the trigeminal formalin
response by eliciting a footpad formalin response and demonstrat-
ing similar Trpv4 dependence using Trpv4/mice (Supplementary
Fig. 1).
3.2. ERK signaling downstream of TRPV4 in TG sensory neurons is
critical for formalin-evoked irritant pain
On the basis of our previous observations of MEK-ERK MAP-
kinase signaling likely downstream of TRPV4 expressed in TG sen-
sory neuron [8], as well as related ﬁndings in sensory neurons and
airway epithelial cells [1,19], we tested the trigeminal formalin
response of mice with dominant-negative MEK expression directed
to neurons, including TG sensory neurons [8]. We observed signif-
icantly reduced nocifensive behavior in response to whisker pad
Fig. 3. Formalin activates heterologously expressed TRPV4. (A) Concentration-dependent curve of Ca2+ inﬂux induced by formalin in N2a cells transfected with rTRPV4 (64–
312 cells/concentration). (B) Ca2+ responses caused by formalin (0.01%) were reversed by pretreatment of the TRPV4 selective inhibitor GSK205 to a level equivalent to control
cells transfected with green ﬂuorescent protein (GFP, 89–133 cells/group). (C) Inhibition of formalin (0.01%)-evoked currents by GSK205 in N2a cells transfected with rTRPV4.
(D) Mean current density measured at +100 and 100 mV in response to formalin (0.01%) and coapplication of GSK205 (6–12 cells/group, ⁄⁄P < .01 vs GFP: formalin and
#P < .05 vs rTRPV4: formalin, 2-tailed t test).
Table 1
Percentage of cultured TG sensory neurons responding to formalin.
Mouse Treatment Responsive TG neurons
WT Formalin 27.66% (143/517)
WT GSK205 (10 lM) + formalin 9.69% (35/361)
TRPV4 KO Formalin 32.12% (62/193)
WT 4a-PDD (5 lM) 24.69% (41/166)
WT A-967079 (10 lM) + formalin 15.79% (66/418)
TRPV4 KO A-967079 (10 lM) + formalin 3.24% (14/432)
TG = trigeminal ganglion; WT = wild type; KO = knockout.
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acute phase (Fig. 2A, B). This result suggests that MEK-ERK is likely
functioning downstream of TRPV4 in TG sensory neurons in forma-
lin-evoked nocifensive behavior, and that this mechanism is rele-
vant for interphase and tonic phase of the formalin response.
Dominant-negative MEK is also effective in central neurons that
transmit pain [16], but this location as a cause of its effect in the
trigeminal formalin response is less likely because of the following
result. We complemented assessment of the dnMEK mouse with
whisker pad injections of speciﬁc MEK inhibitor, U0126 [15]. As a
result, we observed signiﬁcant attenuation of nocifensive behavior.
This effect, for the tonic, neurally mediated phase, was dependent
on the dose of U0126 applied (Fig. 2C, D). The acute phase was sen-
sitive to even the lowest dose of U0126. The acute phase therefore
shows an interesting proﬁle: it is Trpv4 dependent (Fig. 1) but at
the same time not MEK-ERK dependent in TG neurons (Fig. 2A,
B), although robustly MEK-ERK dependent locally in the whisker
pad (Fig. 2C, D). These observations during the acute phase can
be reconciled with TRPV4 functioning in nonneural cells upstream
of MEK-ERK, such as endothelial cells and macrophages, both of
them known to express TRPV4 [2,12,13,27,36]. These cells partici-
pate in sensitizing peripheral nerve endings to formalin. Together,our results suggest that MEK-ERK signaling, downstream of TRPV4-
mediated Ca2+ signaling, functions as a signiﬁcant mechanism in
the organismal trigeminal formalin response. In keeping with this
conclusion, we detected ERK phosphorylation in response to whis-
ker pad injection of formalin within 5 min after injection, both in
whisker pad and TG extracts (Fig. 2E–G). The increased phosphor-
ylation level was sustained in both tissues at the 45 min time point
(Fig. 2E–G). Immunolabeling studies in the TG demonstrated phos-
phorylated ERK to be strictly neuronal (Fig. 2H).
We next asked whether this regulation did indeed depend on
Trpv4. We uncovered afﬁrmative results by use of Trpv4/ mice,
systemic application of HC067047, and whisker pad injections of
GSK205. This was observed at both the 5 and 45 min time points,
indicative of the rapid as well as sustained dynamics of the
TRPV4-dependent regulation (Fig. 2H, I). Conﬁrming the speciﬁcity
of the approach, ERK phosphorylation in TG neurons was reduced
in dnMEK transgenic mice and in mice with whisker pad preinjec-
tions of U0126 in response to whisker pad injections of formalin
(Fig. 2H, J). These results validate the above conclusion of TRPV4
functioning upstream of MEK-ERK. Therefore, this signaling mech-
anism in TG sensory neurons likely underlies the tonic neural
phase of the trigeminal formalin behavioral response.
3.3. TRPV4 is activated by formalin in cultured heterologous cells and
TG sensory neurons
To complement and extend our in vivo studies, we conducted
experiments in dissociated TG sensory neurons and in heterolo-
gous cells with directed expression of TRPV4. For the latter, we
observed a concentration-response relationship for formalin appli-
cation using Ca2+ imaging as a readout in N2a cells (Fig. 3A;
EC50 = 0.00638% formalin). A similar response was detected in
TRPV4-expressing HEK293T cells (data not shown). Control-trans-
fected N2a cells displayed a minimal response to formalin (0.01%).
Fig. 4. Ca2+ inﬂux caused by formalin in TG neurons is TRPV4 dependent. (A) Formalin (0.01%)-evoked Ca2+ inﬂux was attenuated in the presence of TRPV4-selective inhibitor
GSK205 in cultured TG neurons, as well as in TG neurons from Trpv4/ mice. In addition, Ca2+ inﬂux was evoked by the TRPV4 selective agonist 4a-PDD (166–517 cells/
group). (B) A-967079, a speciﬁc TRPA1 inhibitor, led to an attenuated Ca2+ signal in WT TG neurons and to further reduction in neurons from Trpv4/. (C) Formalin (0.01%)-
evoked Ca2+ signaling was not affected by GSK205 in cultured keratinocytes and remained completely unaffected in keratinocytes derived from Trpv4/mice (170–457 cells/
group).
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to background levels by use of 10 lMGSK205 (Fig. 3B). We recapit-
ulated this experiment using patch clamp electrophysiology,
where we noticed the typical outward rectiﬁcation in TRPV4-
expressing N2a cells that were stimulated with formalin. Channel
activation was reverted to background levels in the presence of
10 lMGSK205 (Fig. 3C, D). These results indicate that heterologous
expression of TRPV4 channels is sufﬁcient to confer upon a mini-
mally responsive cell robust responsiveness to dilute formalin. This
response is mediated by TRPV4. TRPV4 is therefore an ionotropic
formalin receptor, or it supplies the critical channel element to a
signaling chain that is present in N2a and HEK293 cells.
We next investigated TG sensory neurons’ response to formalin,
using Ca2+ imaging. We observed an appreciable Ca2+ response to
formalin (0.01%) in 27.66% of the TG neurons (Table 1). This
response rate was not different from that elicited by stimulation
with 4a-PDD (5 lM). Indicative of a critical involvement of TRPV4,
the response rate decreased to 9.7% when applying GSK205
(10 lM). In addition, for responsive cells, intracellular Ca2+ evoked
by formalin was reduced 50% when directly antagonizing TRPV4
with GSK205 (10 lM, preexposure for 15 min). Genetically
encoded absence of Trpv4 led to a slightly increased response rate
as in WT (32.12% vs 27.66%, Table 1). Neurons from Trpv4/ mice
showed a formalin-evoked Ca2+ response that was decreased by
50% in terms of intracellular concentration (Fig. 4A). When exam-
ining the formalin response of dissociated keratinocytes, we found
it to be independent of TRPV4, evidenced by its presence in kerat-
inocytes derived from Trpv4/ mice, and when applying GSK205,
all together not different from that of WT mice (Fig. 4C). Of note,these cells do respond to speciﬁc chemical activation of TRPV4
by 4a-PDD and GSK101 [26].
Thus, TG sensory neurons do respond to formalin directly. This
response is sustained by TRPV4 ion channels that these neurons
express. Antagonism of TRPV4 channels reduced the number of
formalin-responsive neurons and reduced the Ca2+ signal by ½
in the remainder responsive neurons. Genetically encoded
absence of Trpv4 attenuated the Ca2+ signal by ½, not reducing
the number of responsive cells, indicating gene-regulatory com-
pensation in the Trpv4/ pan-null mouse. These ﬁndings suggest
a signiﬁcant contribution of TRPV4 ion channels to the formalin
response of TG sensory neurons, but also the presence of another
formalin-responsive pathway. In the ﬁrst place, the established
formalin receptor, TRPA1 comes to mind as a candidate mecha-
nism to underlie the non-TRPV4-related formalin response
[23,24]. We began to explore this question by using the potent
and speciﬁc TRPA1-inhibitory compound A-967079 [7,39] in our
experiments. It led to an attenuated Ca2+ signal in WT TG neurons
and a further reduction in Trpv4/ TG neurons in response to for-
malin (Fig. 4B). The percentage of responsive cells was reduced
from 27.7% to 15.8% when acutely blocking TRPA1 and to a mere
3.2% in Trpv4/ TG neurons plus TRPA1 inhibitor (Table 1). Thus,
TRPV4 and TRPA1 appear to co-contribute to responsiveness of
TG sensory neurons to formalin.
Together, cellular experiments reveal that directed expression
of TRPV4 is sufﬁcient to render an otherwise minimally responsive
cell formalin responsive, and that the primary sensory neurons of
highest interest in our investigation—TG sensory neurons—can be
activated directly by formalin in a TRPV4-dependent manner.
Fig. 5. TRPV4 and pERK coexpressing TG neurons innervate the whisker pad skin. (A) Immunostaining revealed TRPV4 expression in epidermal keratinocytes and whisker pad
skin nerve ﬁbers, as demonstrated by colabeling with the speciﬁc keratinocyte marker K14 in WTmice (B) and peripheral nerve ﬁber marker PGP9.5 in (Trpv4lox/lox X K14-Cre-
ERtam) keratinocyte-speciﬁc and inducible Trpv4 knockout mice (C) respectively. (D) TRPV4 coexpresses with pERK in TG neurons that innervate the whisker pad, as identiﬁed
with Fast Blue (FB) tracing that is originating from the whisker pad.
Table 2
Increase of TRPV4 and pERK coexpressing TG neurons innervating the whisker pad skin in response to formalin.a
Treatment TRPV4/total pERK/total FB/total TRPV4 + pERK/TRPV4 TRPV4 + pERK + FB/FB
Normal saline 32.15 ± 1.02% 5.44 ± 0.57% 6.53 ± 1.21% 5.67 ± 1.08% 11.25 ± 0.83%
Formalin 5 min 33.72 ± 0.56% 15.54 ± 0.73%⁄⁄⁄ 6.88 ± 0.73% 10.35 ± 0.46%⁄⁄ 18.04 ± 0.61%⁄⁄⁄
TG = trigeminal ganglion.
a Quantiﬁcation illustrates the increase for TRPV4-pERK coexpressing TG neurons of all TRPV4 expressing neurons, also the increase for whisker pad-innervating TRPV4-
pERK coexpressing neurons of all whisker pad-innervating neurons in response to formalin (⁄⁄P < .01 and ⁄⁄⁄P < .001 vs normal saline, 2-tailed t test). Note the unchanged
percentage of TRPV4-expressing neurons and fast blue (FB)-labeled neurons; n = 4 mice/group.
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pad skin
On the basis of these insights, we returned to the TG of control
and formalin-injected mice. First, our immunostaining analysis
revealed TRPV4 to be expressed in both epidermal keratinocytes
and whisker pad skin nerve ﬁbers (Fig. 5A–C). Using trigeminal
ganglia sampled 5 min after whisker pad injections, we combined
coimmunolabeling of TRPV4 and phosphorylated ERK with neural
tracing from the whisker pad skin (Fig. 5D; Table 2). Our results
are telling in that they demonstrate a greater number of phosphor-
ylated ERK-immunoreactive neurons in the population of TRPV4-
expressing sensory neurons, an increase of 100% (Table 2, 5.67%
vs 10.35%). Importantly, in TRPV4-expressing neurons that colabel
with whisker pad injected tracer, we found an increase of phos-
phorylated ERK by 75% (11.25% vs 18.04%). This is an interesting
ﬁnding when compared to all TG sensory neurons, where phos-
phorylated ERK expressing neurons tripled from 5.44% to 15.54%
(Table 2). This means that whisker pad injections of formalin can
possibly activate TG sensory neurons that do not innervate thewhisker pad, which is even more astounding given the time inter-
val between whisker pad injection of formalin and sampling of the
TG, namely 5 min. As a measure of the validity of our approach,
there was no signiﬁcant change in abundance of neurons labeled
with neural tracer (6.53% vs 6.88%) and of neurons showing appre-
ciable TRPV4 expression, evidenced by the fact that TRPV4 could be
detected in a straightforward manner by simple 2-step immunola-
beling (32.15% vs 33.72%). Together, these ﬁndings indicate that
TRPV4-expressing TG sensory neurons that innervate the whisker
pad skin become activated to phosphorylate ERK within 5 min
after formalin injection. This activation is likely to underlie the
TRPV4-dependent neurally mediated tonic phase of the trigeminal
formalin response that we have characterized here.
3.5. Co-contribution of TRPA1 and TRPV4 to the trigeminal formalin
response
On the basis of our ﬁndings of a co-contribution of TRPA1 and
TRPV4 to the formalin response of TG sensory neurons, we com-
pared nocifensive behavior in pan-null mice for both genes, then
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attenuation of nocifensive behavior in Trpv4/ and Trpa1/ mice
to similar degree of the formalin response (Fig. 6A, B). When pre-
treated with whisker pad injection of TRPV4-inhibitor, GSK205
(Fig. 1G, H), only the tonic phase was signiﬁcantly attenuated in
Trpa1/mice (Fig. 6A, B). This suggests that both channels co-con-
tribute to the in vivo effects of formalin, sustaining in particular the
tonic phase of the response. We also investigated pERK expression
in TG sensory neurons as the intracellular downstream signaling
function. We found a signiﬁcant percentage reduction in both null
genotypes, indicating that Ca2+ inﬂux via either channel can activate
MEK-ERK MAP-kinase signaling in TG sensory neurons (Fig. 6C, D).
Our in vivo ﬁndings therefore dovetail with the concept of a co-con-
tribution of TRPA1 and TRPV4 to the trigeminal formalin response
in vivo.
4. Discussion
Here we demonstrate an important role for TRPV4 ion channels
in the trigeminal formalin pain response. TRPV4 is contributory to
all phases of the trigeminal formalin pain response. Its functional
expression in TG sensory neurons is key for the protracted, neu-
rally mediated tonic phase of pain behavior. TRPV4 channels
function upstream of MEK-ERK phosphorylation in whisker pad–
innervating TG sensory neurons to evoke the delayed phase of
the pain behavior. In keeping with a key role in transduction of
the irritant stimulus, TRPV4 expression in heterologous cellular
systems confers robust responsiveness to formalin. TG sensory
neurons respond to formalin directly with Ca2+ inﬂux in aFig. 6. Co-contribution of TRPA1 and TRPV4 to the trigeminal formalin response. (A, B)
lacking Trpa1, and this attenuation was further reduced by subcutaneous pretreatment w
formalin, $P < .05 vs TRPA1 KO: formalin, and #P < .01 vs TRPV4 KO: formalin; n = 5–
signiﬁcantly reduced in mice lacking Trpa1 (n = 4–5/group, ⁄⁄⁄P < .001 vs WT: NS, #P < .05
for (A) and (B), and 2-tailed t test was used for (C) and (D).TRPV4-dependent manner. These results imply TRPV4 as a novel
irritant receptor in the trigeminal system in addition to the known
TRPA1 [3,24]. Targeting TRPV4 for trigeminal pain disorders might
be a rational and possibly fruitful new strategy.
With respect to mechanisms of action of formalin on TG sensory
neurons, future studies can address the following interesting ques-
tions: What is the mechanism of the demonstrated co-contribution
of TRPV4 and TRPA1 to the trigeminal formalin response (Ca2+ sig-
naling mechanism, channel mechanism, membrane mechanism)?
For TRPV4 channel activation mechanisms by formalin, can direct
activation be deconstructed, or is formalin acting on a yet-to-be-
identiﬁed receptor, other membrane protein, or membrane–lipid
complex, which subsequently activates TRPV4?
In regard to trigeminal pain disorders, TRPV4 is likely a mole-
cule of interest that regulates the transformation of TG sensory
neurons into pain generators. In this process, the Ca2+-permeable
channel functions upstream of MEK-ERK MAP-kinase signaling.
This is in keeping with another study that we have conducted
involving longer-term inﬂammation of the TMJ using complete
Freund adjuvant [8]. In this model, which lasts almost 2 weeks,
we observed longer-term changes of pain-enhancing gene regula-
tion in the TG, dependent on TRPV4. MEK-ERK phosphorylation
was also found dependent on TRPV4. In the current study,
MEK-ERK phosphorylation depends again on Trpv4, but the time
dynamics of the formalin model is so rapid—45 min—that gene
dysregulation cannot be implied as causative. However, we are
struck by the common feature of both studies, namely that TRPV4
is critical for pain behavior, that its expression in TG sensory neu-
rons appears key, and that MEK-ERK signals downstream of TRPV4Signiﬁcant attenuation of irritant pain induced by formalin was observed in mice
ith the TRPV4 inhibitor GSK205 for the tonic phase (⁄⁄P < .01 and ⁄⁄⁄P < .001 vs WT:
9/group). (C, D) Increase of pERK in TG neurons caused by formalin injection is
and ###P < .01 vs WT: formalin). One-way ANOVA with Tukey post hoc test was used
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means that TRPV4 is now a more validated, bona ﬁde target for
relief of pain [18] in the trigeminal system. This includes head-
aches (eg, migraines and tension-type headaches), TMJ pain, sinus
pain, trigeminal neuropathic pain, trigeminal neuralgia, tooth pain,
and orofacial sensory disorders with a pain-equivalent component
(eg, burning mouth syndrome). The relative contribution of TRPV4
to these pain disorders needs to be established in future studies,
which can now be conducted in a more rational manner, based
on our results presented here and in our previous study [8]. We
note that mechanical hypersensitivity, such as hyperalgesia, allo-
dynia, and inﬂammation-facilitated pain, are a common feature
of these disorders. This clinical argument reinvigorates TRPV4 an
appealing target molecule.
Beyond classic trigeminal pain disorders, TRPV4 might be func-
tional in trigeminal irritation disorders evoked by airborne expo-
sures of trigeminally innervated external barriers (eg, cornea and
conjunctiva of the eye; mucous membranes of the nasal cavity,
nasopharynx, sinuses, oral cavity, and pharynx) to formalin and
related electrophilic irritants [19].
Speciﬁc inhibition of TRPV4 can therefore be a novel therapeu-
tic principle for trigeminal pain as well as irritation disorders.
Especially for the latter, topical application of TRPV4 inhibitors
might be a suitable and effective remedy.
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